Updates are available Correction dated 2024-09-04
Click to view Correction: https://doi.org/10.1038/s44276-024-00083-5
-
Authors
Gehrchen, Mathilde Louise https://orcid.org/0000-0002-6528-1259
Berg, Tobias
Garly, Rasmus
Jensen, Maj-Britt
Eßer-Naumann, Saskia
Rønlev, Jeanette Dupont
Nielsen, Hanne Melgaard
Knoop, Ann
Kümler, Iben
- License Information
-
More Information
Article History
Received: 14 May 2024
Revised: 17 May 2024
Accepted: 4 June 2024
First Online: 20 June 2024
Change Date: 4 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44276-024-00083-5
Competing interests
: MLG: Unrestricted research grant from the Danish Cancer Society. TB: Institutional grants: Pfizer, Astra Zeneca, Novartis, Samsung Bioepis, Seattle Genetics, Merck, Eli Lilly and Danish Cancer Society. Personal grants (advisory board/presentation): Merck, Astra Zeneca, Pfizer and Novartis. Personal grants (travel): Daiichi Sankyo. RG: None. MJ: Meeting expenses and advisory board, Novartis. SN: None. JDR: None. HMN: None. AK: Institutional grants from Pfizer, AstraZeneca, Merck, Eli Lilly, Seattle Genetics, Roche, Novartis. Personal grants from Astra Zeneca and Daiichi Sankyo (travel + advisory board), MSD, Novartis, Seagen (Advisory Board). IK: None.
: The present study is retrospective, register based, and did not involve contact with patients. The study was approved by the Capital Region’s Center for Health (R-22036282) and the Capital Region’s research overview.
